Skip to main content

Advertisement

SpringerLink
Log in

The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The aim of our study was to evaluate the effect of two polymorphisms in the estrogen receptor alpha, PvuII and XbaI, on the development of prostate cancer within Slovak population, as well as their correlation with selected clinical characteristics. The study was performed using 311 prostate cancer patients and 256 healthy male controls. Both polymorphisms were significantly associated with higher risk of prostate cancer development. At the same time, the CC genotype of PvuII polymorphism (OR = 1.98; 95 % CI 0.94–4.21; p = 0.05) and the AG genotype of XbaI polymorphism (OR = 1.74; 95 % CI 1.0–3.02; p = 0.04) significantly contributed to the development of low-grade carcinoma, while the AG and GG genotypes of the XbaI polymorphism contributed mainly to the development of high-grade prostate cancer (OR = 1.83; 95 % CI 1.12–3.01; p = 0.01 and OR = 2.13; 95 % CI 1.06–4.19; p = 0.03, respectively). Similarly, the AG and GG genotypes of XbaI polymorphism showed significant association with prostate cancer in patients with serum PSA level ≥10 ng/ml. Both polymorphisms were found at the same time to be more frequent in patients diagnosed before the age of 60. We conclude on the basis of these results that PvuII and XbaI polymorphisms of estrogen receptor alpha might be associated with prostate cancer risk within Slovak population. Although this is a pilot study and, as such, more detailed investigations are needed to confirm the role of these polymorphisms in prostate cancer development and progression within said Slovak population, our results might still provide a valuable basis for further research with larger patient groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J, Todorović V, Borojević N, Croitoru A, South Eastern European Research Oncology Group (2011) Cancer epidemiology in Central, South and Eastern European countries. Croat Med J 52:478–487. doi:10.3325/cmj.2011.52.478

    Article  PubMed  Google Scholar 

  2. Hsing AW, Chokkalingam AP (2008) Prostate cancer epidemiology. Front Biosci 11:1388–1413

    Article  Google Scholar 

  3. Schaid DJ (2004) The complex genetic epidemiological of prostate cancer. Hum Mol Genet 13 Spec No 1:R103–R121

    Article  PubMed  Google Scholar 

  4. Bosland MC (2000) The role of steroid hormones in prostate cancinogenesis. J Natl Cancer Inst Monogr 27:39–66

    Article  PubMed  CAS  Google Scholar 

  5. Soni A, Bansal A, Mishra AK, Batra J, Singh LC, Chakraborty A, Yadav DS, Mohanty NK, Saxena S (2012) Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population. Genet Test Mol Biomarkers 16:835–840. doi:10.1089/gtmb.2011.0322

    Article  PubMed  CAS  Google Scholar 

  6. Monteiro C, Sousa MV, Ribeiro R, Maurício J, Fraga A, Medeiros R (2013) Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer. Med Oncol 30:490. doi:10.1007/s12032-013-0490-2

    Article  PubMed  Google Scholar 

  7. Li Q, Zhu Y, He J, Wang M, Zhu M, Shi T, Qiu L, Ye D, Wei Q (2013) Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis. Mol Biol Rep 40(5):3597–3608. doi:10.1007/s11033-012-2434-x

    Article  PubMed  CAS  Google Scholar 

  8. Söderström T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, Rane A (2002) 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics. 12:307–312

    Article  PubMed  Google Scholar 

  9. Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81–89

    Article  PubMed  CAS  Google Scholar 

  10. Carruba G (2007) Estrogen and prostate cancer: an eclipse truth in an androgen-dominated scenario. J Cell Biochem 102:899–911

    Article  PubMed  CAS  Google Scholar 

  11. Ellem SJ, Risbridger GP (2009) The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 1155:174–186

    Article  PubMed  CAS  Google Scholar 

  12. Ho SM, Leung YK, Chung I (2006) Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann N Y Acad Sci 1089:177–193

    Article  PubMed  CAS  Google Scholar 

  13. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Arenas MI, Paniagua R (2001) Estrogen receptors α and ß in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 168:447–454

    Article  PubMed  CAS  Google Scholar 

  14. Vanacker JM, Pettersson K, Gustafsson JA, Laudet V (1999) Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ. EMBO J 18:4270–4279

    Article  PubMed  CAS  Google Scholar 

  15. Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, Cunha G (2001) Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 229:432–442

    Article  PubMed  CAS  Google Scholar 

  16. Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, Cunha G, Wong YZ (2001) Evidence that epithelial and mesenchymal estrogen receptor-α mediates effects of estrogen on prostatic epithelium. Dev Biol 229:432–442

    Article  PubMed  CAS  Google Scholar 

  17. McPherson S, Wang H, Jones M, Pedersen J, Iismaa T, Wreford N, Simpson E, Risbridger G (2001) Elevated androgens and prolactin in aromatase deficient (ArKO) mice cause enlargement but not malignancy of the prostate gland. Endocrinol 142:2458–2467

    Article  CAS  Google Scholar 

  18. McPherson S, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbrider GP (2007) Essential role for estrogen receptor β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinol 148:54–566

    Google Scholar 

  19. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H (1996) Association of bone mineral density with polymorphism of estrogen receptor gene. J Bone Miner Res 11:306–311

    Article  PubMed  CAS  Google Scholar 

  20. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S (2012) Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog 51(Suppl 1):E104–E117

    Article  PubMed  CAS  Google Scholar 

  21. Herrington DM, Howard TD, Brosnihan KB, McDonnel DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER (2002) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105:1879–1882

    Article  PubMed  CAS  Google Scholar 

  22. Beleza-Meireles A, Omrani D, Kockum I, Frisen L, Lagerstedt K, Nordenskjold A (2006) Polymorphisms of estrogen receptor beta gene are associated with hypospadias. J Endocrinol Invest 29:5–10

    PubMed  CAS  Google Scholar 

  23. Modungo F, Weissfeld JL, Trump DL, Zmuda JM, Shea P et al (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092–3096

    Google Scholar 

  24. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T (2004) Genetic polymorphism of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24:2431–2437

    PubMed  CAS  Google Scholar 

  25. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, Leach RJ (2006) Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol 175:523–527

    Article  PubMed  CAS  Google Scholar 

  26. Balistreri CR, Caruso C, Carruba G, Miceli V, Candore G (2011) Genotyping of sex hormone-related pathways in benign and malignant human prostate tissue: data of a preliminary study. J Integr Biol 15:369–374

    CAS  Google Scholar 

  27. Sissung TM, Danesi R, Kirkland T, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD (2011) Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab 96:E368–E372

    Article  PubMed  CAS  Google Scholar 

  28. Gupta L, Thakur H, Sobti RC, Seth A, Singh SK (2010) Role of genetic polymorphism of estrogen receptor-α gene and the risk of prostate cancer in north Indian population. Mol Cell Biochem 335:255–261

    Article  PubMed  CAS  Google Scholar 

  29. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S, Dunning AM, Luben RN, Khaw KT, Day NE, Wareham NJ, Bingham SA (2006) Phytoestrogen exposure, polymorphism in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 56:31–39

    Article  PubMed  CAS  Google Scholar 

  30. Sasaki M, Tanaka Y, Sakuragi N, Daiya R (2003) Eur J Clin Pharmacol 59:389–393

    Article  PubMed  CAS  Google Scholar 

  31. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R (2003) Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog 37:202–208

    Article  PubMed  CAS  Google Scholar 

  32. Beuten J, Gelfond JAL, Franke JL et al (2009) Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 18:1869–1880

    Article  PubMed  CAS  Google Scholar 

  33. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H (2003) Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate cancer risk in a Japanese population. Cancer 98:1411–1416

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Dr N. A. Yeboah for critical reading of the manuscript. This study was supported by Project “Competence Center for research and development in the field of diagnostics and therapy of oncological diseases,” ITMS: 26220220153, co-funded from EU sources and European Regional Development Fund and by Projects supported by Ministry of Health of the Slovak Republic 2007/45-UK-10 and 2007/57-UK-17.

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic

    Jana Jurečeková, Monika Kmeťová Sivoňová, Andrea Evinová & Dušan Dobrota

  2. Department of Urology, Jessenius Faculty of Medicine and University Hospital Martin, Comenius University in Bratislava, Martin, Slovak Republic

    Ján Kliment

Authors
  1. Jana Jurečeková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monika Kmeťová Sivoňová
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Evinová
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ján Kliment
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dušan Dobrota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jana Jurečeková.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jurečeková, J., Sivoňová, M.K., Evinová, A. et al. The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population. Mol Cell Biochem 381, 201–207 (2013). https://doi.org/10.1007/s11010-013-1703-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-013-1703-x

Keywords

Search

Navigation